Audentes Therapeutics (BOLD) Releases Quarterly Earnings Results, Misses Expectations By $0.23 EPS

Audentes Therapeutics (NASDAQ:BOLD) issued its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.23), Briefing.com reports. During the same period in the previous year, the business earned ($0.74) earnings per share.

BOLD stock traded down $0.93 during trading on Friday, reaching $35.12. 272,400 shares of the stock traded hands, compared to its average volume of 547,706. Audentes Therapeutics has a 52-week low of $17.95 and a 52-week high of $46.18. The company has a market cap of $1.57 billion, a PE ratio of -10.33 and a beta of 1.85.

Several equities analysts recently issued reports on BOLD shares. ValuEngine raised Audentes Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Friday, May 10th. Wedbush boosted their price target on Audentes Therapeutics from $52.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, April 9th. BMO Capital Markets set a $47.00 price target on Audentes Therapeutics and gave the stock a “buy” rating in a report on Wednesday, May 8th. HC Wainwright set a $48.00 price target on Audentes Therapeutics and gave the stock a “buy” rating in a report on Wednesday, May 8th. Finally, Zacks Investment Research lowered Audentes Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, March 12th. Two research analysts have rated the stock with a sell rating, three have issued a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $39.92.

In related news, VP Suyash Prasad sold 10,000 shares of the stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $36.98, for a total value of $369,800.00. Following the completion of the transaction, the vice president now owns 28,236 shares of the company’s stock, valued at $1,044,167.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Louis G. Lange sold 20,000 shares of the stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $36.00, for a total value of $720,000.00. Following the completion of the transaction, the director now directly owns 306,099 shares of the company’s stock, valued at approximately $11,019,564. The disclosure for this sale can be found here. 5.30% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the stock. NumerixS Investment Technologies Inc boosted its holdings in Audentes Therapeutics by 1,200.0% in the fourth quarter. NumerixS Investment Technologies Inc now owns 1,300 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 1,200 shares during the last quarter. BlueMountain Capital Management LLC acquired a new stake in Audentes Therapeutics during the first quarter valued at approximately $137,000. Amundi Pioneer Asset Management Inc. acquired a new stake in Audentes Therapeutics during the fourth quarter valued at approximately $92,000. Great West Life Assurance Co. Can raised its stake in Audentes Therapeutics by 96.0% during the fourth quarter. Great West Life Assurance Co. Can now owns 4,726 shares of the biotechnology company’s stock valued at $97,000 after buying an additional 2,315 shares in the last quarter. Finally, Principal Financial Group Inc. acquired a new stake in Audentes Therapeutics during the first quarter valued at approximately $229,000. 98.71% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This article was posted by Rockland Register and is the property of of Rockland Register. If you are accessing this article on another domain, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this article can be viewed at https://rocklandregister.com/2019/05/31/audentes-therapeutics-bold-posts-earnings-results.html.

About Audentes Therapeutics

Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.

Read More: What is the S&P 500 Index?

Earnings History for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.